Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medtronic's Ending Cash Position for the quarter that ended in Apr. 2026 was R$9,811 Mil.
Medtronic's quarterly Ending Cash Position
declined
from Oct. 2025 (R$6,901 Mil) to Jan. 2026 (R$6,115 Mil) but then
increased
from Jan. 2026 (R$6,115 Mil) to Apr. 2026 (R$9,811 Mil).
Medtronic's annual Ending Cash Position
increased
from Apr. 2024 (R$6,587 Mil) to Apr. 2025 (R$12,843 Mil) but then
declined
from Apr. 2025 (R$12,843 Mil) to Apr. 2026 (R$9,811 Mil).
The historical data trend for Medtronic's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
Medtronic's Ending Cash Position for the fiscal year that ended in Apr. 2026 is calculated as
What does a Ending Cash Position of R$9,811 Mil mean?
Medtronic (BSP:MDTC34) has a Ending Cash Position of R$9,811 Mil as of Apr. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Medtronic and its competitors.
Is Medtronic's Ending Cash Position too high?
Medtronic's current Ending Cash Position is R$9,811 Mil. Overall, Medtronic has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medtronic's Ending Cash Position compare to SYK and BSX?
Medtronic's Ending Cash Position of R$9,811 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Medtronic and its competitors. Medtronic's current Ending Cash Position is R$9,811 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtronic stock overvalued right now?
Based on GuruFocus' analysis, Medtronic (BSP:MDTC34) is currently considered Fairly Valued. The stock's GF Value™ is R$62.24, compared to a current price of R$58.74 — trading 5.6% below its estimated fair value. The current Ending Cash Position is R$9,811 Mil. Medtronic's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Medtronic (BSP:MDTC34), the current Ending Cash Position is R$9,811 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medtronic (BSP:MDTC34) Overvalued in 2026?
Based on GuruFocus' analysis, Medtronic stock appears to be undervalued.
The current stock price of R$58.74 is trading 5.6% below its estimated GF Value™ of R$62.24.
GuruFocus considers Medtronic to be Fairly Valued.
Key valuation signals for BSP:MDTC34:
Ending Cash Position: R$9,811 Mil
GF Value™: R$62.24 vs. price of R$58.74 (5.6% below fair value)
No single metric tells the full story. See the BSP:MDTC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
73GF Score
Get the complete analysis for BSP:MDTC34
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:MDTC34 has been successfully added to your 
